Nitric oxide generation affects pro- and anti-angiogenic growth factor expression in primary human trophoblast
- PMID: 21963217
- PMCID: PMC3269960
- DOI: 10.1016/j.placenta.2011.08.008
Nitric oxide generation affects pro- and anti-angiogenic growth factor expression in primary human trophoblast
Abstract
Objectives: Preeclampsia is associated with reduced trophoblast placenta growth factor (PGF) expression, elevated soluble fms-like tyrosine kinase-1 (sFlt-1) and decreased bioactivity of nitric oxide (NO). Elevated sFlt-1 reduces bio-availability of PGF and vascular endothelial growth factor (VEGF) leading to maternal endothelial dysfunction. Although NO can regulate gene expression, its ability to regulate trophoblast expression of angiogenic growth factors is not known.
Study design: Human primary term trophoblast and JEG-3 choriocarcinoma cells were cultured under 21%O(2) or 1%O(2) conditions in the presence or absence of NO donor (SNP) or inhibitor (L-NAME). Effects on PGF, VEGF and Flt-1 isoform mRNA expression were determined by quantitative real-time PCR. Changes in expression of soluble protein isoforms of FLT-1 was monitored by ELISA.
Results: Hypoxia decreased PGF mRNA but increased VEGF, sFlt-1 and Flt-1 mRNA expression in trophoblast. Generation of NO in trophoblast under 1%O(2) culture conditions significantly reversed sFlt-1 mRNA and protein expression, independent of mFlt-1. Conversely NO generation in hypoxic trophoblast increased VEGF and PGF mRNA expression.
Conclusions: NO production in primary human trophoblast cultures had divergent effects on pro-angiogenic (PGF, VEGF) versus anti-angiogenic (sFlt-1) mRNA expression, resulting in an enhanced pro-angiogenic gene expression environment in vitro.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Figures




Similar articles
-
Edaravone inhibits hypoxia-induced trophoblast-soluble Fms-like tyrosine kinase 1 expression: a possible therapeutic approach to preeclampsia.Placenta. 2014 Jul;35(7):476-82. doi: 10.1016/j.placenta.2014.04.002. Epub 2014 Apr 29. Placenta. 2014. PMID: 24840734
-
Hypoxia down-regulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression: molecular evidence for "placental hyperoxia" in intrauterine growth restriction.Lab Invest. 1999 Feb;79(2):151-70. Lab Invest. 1999. PMID: 10068204
-
Role of VEGF receptor-1 (Flt-1) in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells.Lab Invest. 1997 Jun;76(6):779-91. Lab Invest. 1997. PMID: 9194854
-
The perinatal implications of angiogenic factors.Curr Opin Obstet Gynecol. 2009 Apr;21(2):111-6. doi: 10.1097/GCO.0b013e328328cf7d. Curr Opin Obstet Gynecol. 2009. PMID: 19996864 Review.
-
Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review.Placenta. 2000 Mar-Apr;21 Suppl A:S16-24. doi: 10.1053/plac.1999.0524. Placenta. 2000. PMID: 10831117 Review.
Cited by
-
Malaria in pregnancy alters l-arginine bioavailability and placental vascular development.Sci Transl Med. 2018 Mar 7;10(431):eaan6007. doi: 10.1126/scitranslmed.aan6007. Sci Transl Med. 2018. PMID: 29514999 Free PMC article.
-
Inflammation in Preeclampsia: Genetic Biomarkers, Mechanisms, and Therapeutic Strategies.Front Immunol. 2022 Jul 8;13:883404. doi: 10.3389/fimmu.2022.883404. eCollection 2022. Front Immunol. 2022. PMID: 35880174 Free PMC article.
-
Maternal perfluorooctane sulfonic acid exposure during rat pregnancy causes hypersensitivity to angiotensin II and attenuation of endothelium-dependent vasodilation in the uterine arteries †.Biol Reprod. 2022 Oct 11;107(4):1072-1083. doi: 10.1093/biolre/ioac141. Biol Reprod. 2022. PMID: 35835584 Free PMC article.
-
Testosterone alters maternal vascular adaptations: role of the endothelial NO system.Hypertension. 2013 Mar;61(3):647-54. doi: 10.1161/HYPERTENSIONAHA.111.00486. Epub 2013 Jan 21. Hypertension. 2013. PMID: 23339170 Free PMC article.
-
Pathophysiology of Preeclampsia and L-Arginine/L-Citrulline Supplementation as a Potential Strategy to Improve Birth Outcomes.Adv Exp Med Biol. 2023;1428:127-148. doi: 10.1007/978-3-031-32554-0_6. Adv Exp Med Biol. 2023. PMID: 37466772 Review.
References
-
- ACOG: ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia Number 33, January 2002 American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 2002;77:67–75. - PubMed
-
- Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2008;294:H541–H550. - PubMed
-
- Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–83. - PubMed
-
- Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, Blink AL, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Urinary placental growth factor and risk of preeclampsia. Jama. 2005;293:77–85. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous